In the summer of 2026, the Trump administration is pushing hard on two opposite drug-pricing fronts at the same time: in Europe, working with the pharmaceutical industry to lift prices; in the United States, swinging a tariff stick at the very same drug companies. This is not policy chaos — it is a deliberate two-front strategy, and the contradiction at its core lays bare the full logic of Trump's second-term interplay between transactional diplomacy abroad and populist politics at home.
In Europe: Using the Tariff Lever to Unravel Price Controls
In Europe, the pharmaceutical industry is preparing, hand in hand with U.S. trade officials, to launch a new round of Section 301 tariff investigations. The targets are the European countries that have held drug prices down through quiet negotiations — Britain has already conceded, pledging to boost spending on new drugs in exchange for three years of zero-tariff market access, and Germany has become the next bullseye.
The strategy does not actually impose tariffs on medicines — zero tariffs are in fact the core of the industry's lobbying goal. Its elegance lies elsewhere: the threat of a 301 investigation is used to drag each country to the negotiating table, and then "zero-tariff market access" is offered as the chip to be cashed in for the dismantling of European price controls. As a former U.S. Trade Representative official put it bluntly: "There is currently very intensive lobbying going on, the pharmaceutical industry is pushing hard to launch a 301 investigation."
Last month, Washington opened an investigation targeting Germany's "long-term underpayment for innovative medicines." France, Spain and Italy have been queued up as the next targets. The head of PhRMA, the U.S. industry's largest lobbying organization, has urged the government to "continue pushing for strong trade agreements so that our trading partners stop free-riding on American innovation."
The underlying logic rests on a basic Trump-era judgment: American citizens have long been subsidizing European drug costs. He believes that European governments, by using their pricing power to push prices down, are in effect free-riding on the innovation dividend that high U.S. prices make possible. The goal, then, is straightforward — make the two regions pay the same.
Britain has been positioned as the template: the pharmaceutical industry trades tariff relief for a British government commitment to raise drug spending. German Chancellor Friedrich Merz has explicitly warned Washington not to try to break the "Turnberry trade truce" — the agreement that caps U.S.–EU pharmaceutical tariffs at 15% — but officials familiar with White House thinking note that there is "no legal restriction" on targeting individual member states, and that the administration could even single out a core German industry such as automobiles as the tariff target.
The threat of a 301 investigation is not the goal itself — it is the instrument that drags each European country to the table. The core of the play is to trade "zero-tariff market access" for the dismantling of European price controls. The 15% cap in the Turnberry agreement is a hard constraint, but room to maneuver exists: targeting individual member states rather than the EU as a whole, selecting products outside the agreement's coverage, and the "political choice" option of treating pharmaceuticals as a new issue in a different domain.
At Home: Populist Pressure on the Same Companies
Inside the United States, Trump's posture toward the pharmaceutical industry is the opposite — or rather, the same posture pointed in a different direction.
He has threatened to impose triple-digit tariffs on global drugmakers unless they bring down costs for American consumers — an offensive that has already forced the industry into seventeen price-cut agreements. He has also ordered Congress to codify his "most-favored-nation" drug-pricing policy into law, aiming to align U.S. prices with those in parts of Europe. The White House is further reviewing a proposal that would require companies to rebate sums to the federal Medicare program whenever U.S. prices run higher than those in other wealthy countries — a move that will almost certainly invite legal challenges.
Last week, a congressional committee opened an investigation — citing national security — into five drugmakers, including Merck and AbbVie, accusing them of running clinical trials in China that "have fueled this communist country's military capabilities."
"It is rather unusual for a Republican administration to launch a full-spectrum offensive against the pharmaceutical industry — an offensive that could upend its entire business model. Democrats have always despised the industry… and now Trump is attacking them from a populist angle… it really feels as if they are under siege."
The Two-Front Logic: Coexistence of Pressure and Cooperation
Placing the European and American threads side by side reveals a key fact: the pharmaceutical industry has not pushed back in the face of domestic populist pressure. The reason is simple — the U.S. market is critical to its revenue, and the Trump administration's European strategy happens to be opening up new market space for the industry at the same time.
"The pharmaceutical industry is looking for areas where it can work with the government and pushing back on issues where they might disagree. It's like your relationship with your brother-in-law… you may not agree on everything, but you find ways to cooperate so that Thanksgiving dinner doesn't get awkward."
Trump simultaneously plays the role of "populist fighter" and "industry ally" on two fronts — appealing to midterm voters who care about healthcare costs, while opening European markets for the same industry. This seemingly contradictory behavior pattern has surfaced repeatedly in Trump's second term: domestically, populist rhetoric is used to attack an industry in order to harvest political capital; internationally, government power is used to open up markets for that same industry.
Legal Constraints and Institutional Gaps
Germany is not entirely defenseless against the U.S. tariff threat. The 15% cap set by the Turnberry agreement is a hard constraint, but officials familiar with the White House's thinking point to three institutional gaps: first, action can be taken against individual member states rather than the EU as a whole; second, products outside the agreement's coverage can be singled out; and third, the "political choice" trade expert mentioned earlier — the U.S. government can choose to ignore the agreement's framework and recharacterize the pharmaceutical question as a "new issue in a different domain."
This means Trump has considerable operational latitude on drug pricing. He can take the hard line — slap fresh tariffs on German automobiles to force concessions on drug prices. Or he can take the middle road — use the threat of tariff investigations to drag European countries one by one to the table, then trade commercial interest for price concessions.
Whichever path he chooses, the core logic is unchanged: redefine the global drug-pricing problem as a trade problem, then use America's market power and tariff weapons to redraw the price map.
The simultaneous aggressiveness on the European and domestic fronts is not policy confusion but a coordinated two-front strategy: in Europe, the administration is a partner to the industry in lifting prices; at home, it is a populist adversary demanding cuts. The industry accepts the domestic pressure because Europe's new market space covers the cost — and the administration's institutional engineering makes both moves fit within the existing legal architecture. The next inflection point will be whether Germany's pushback, or a similar European objection, closes one of those institutional gaps before the November midterms.